BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nimczick M, Decker M. New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds. ChemMedChem 2015;10:773-86. [DOI: 10.1002/cmdc.201500041] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Morales P, Hernandez-Folgado L, Goya P, Jagerovic N. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. Expert Opin Ther Pat 2016;26:843-56. [PMID: 27215781 DOI: 10.1080/13543776.2016.1193157] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
2 Botta J, Appelhans J, Mccormick PJ. Continuing challenges in targeting oligomeric GPCR-based drugs. Oligomerization in Health and Disease: From Enzymes to G Protein-Coupled Receptors. Elsevier; 2020. pp. 213-45. [DOI: 10.1016/bs.pmbts.2019.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Moreno E, Cavic M, Krivokuca A, Casadó V, Canela E. The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet? Front Pharmacol 2019;10:339. [PMID: 31024307 DOI: 10.3389/fphar.2019.00339] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
4 Dvorácskó S, Keresztes A, Mollica A, Stefanucci A, Macedonio G, Pieretti S, Zádor F, Walter FR, Deli MA, Kékesi G, Bánki L, Tuboly G, Horváth G, Tömböly C. Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors. Eur J Med Chem 2019;178:571-88. [PMID: 31220675 DOI: 10.1016/j.ejmech.2019.05.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
5 Decker M, Muñoz-Torrero D. Special Issue: "Molecules against Alzheimer". Molecules 2016;21:E1736. [PMID: 27999295 DOI: 10.3390/molecules21121736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Murillo-Rodríguez E, Di Marzo V, Machado S, Rocha NB, Veras AB, Neto GAM, Budde H, Arias-Carrión O, Arankowsky-Sandoval G. Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation. Front Mol Neurosci 2017;10:152. [PMID: 28611585 DOI: 10.3389/fnmol.2017.00152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
7 Dolles D, Strasser A, Wittmann H, Marinelli O, Nabissi M, Pertwee RG, Decker M. The First Photochromic Affinity Switch for the Human Cannabinoid Receptor 2. Adv Therap 2018;1:1700032. [DOI: 10.1002/adtp.201700032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
8 Romanucci V, Di Fabio G, Zarrelli A. A New Class of Synthetic Flavonolignan-Like Dimers: Still Few Molecules, but with Attractive Properties. Molecules 2018;24:E108. [PMID: 30597952 DOI: 10.3390/molecules24010108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Páez JA, Campillo NE. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases. CMC 2019;26:3300-40. [DOI: 10.2174/0929867325666180226095132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chanphai P, Agudelo D, Vesper AR, Bérubé G, Tajmir-Riahi HA. Testosterone and its dimers alter tRNA morphology. J Pharm Biomed Anal 2017;134:269-74. [PMID: 27930994 DOI: 10.1016/j.jpba.2016.11.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
11 Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Front Neurosci 2016;10:406. [PMID: 27679556 DOI: 10.3389/fnins.2016.00406] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
12 Newman AH, Battiti FO, Bonifazi A. 2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts. J Med Chem 2020;63:1779-97. [PMID: 31499001 DOI: 10.1021/acs.jmedchem.9b01105] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
13 Dolles D, Hoffmann M, Gunesch S, Marinelli O, Möller J, Santoni G, Chatonnet A, Lohse MJ, Wittmann HJ, Strasser A, Nabissi M, Maurice T, Decker M. Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles. J Med Chem 2018;61:1646-63. [PMID: 29400965 DOI: 10.1021/acs.jmedchem.7b01760] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
14 Morales P, Jagerovic N. Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opin Drug Discov 2020;15:917-30. [PMID: 32336154 DOI: 10.1080/17460441.2020.1752178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
15 Scheiner M, Dolles D, Gunesch S, Hoffmann M, Nabissi M, Marinelli O, Naldi M, Bartolini M, Petralla S, Poeta E, Monti B, Falkeis C, Vieth M, Hübner H, Gmeiner P, Maitra R, Maurice T, Decker M. Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo. J Med Chem 2019;62:9078-102. [PMID: 31609608 DOI: 10.1021/acs.jmedchem.9b00623] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
16 Dolles D, Decker M. Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors. Design of Hybrid Molecules for Drug Development. Elsevier; 2017. pp. 137-65. [DOI: 10.1016/b978-0-08-101011-2.00005-2] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. Prog Neurobiol 2019;174:53-89. [PMID: 30599179 DOI: 10.1016/j.pneurobio.2018.12.006] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 26.0] [Reference Citation Analysis]
18 Muñoz-torrero D. Multitarget Anti-Alzheimer Hybrid Compounds. Design of Hybrid Molecules for Drug Development. Elsevier; 2017. pp. 167-92. [DOI: 10.1016/b978-0-08-101011-2.00006-4] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
19 Basagni F, Rosini M, Decker M. Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes. ChemMedChem 2020;15:1374-89. [PMID: 32578963 DOI: 10.1002/cmdc.202000298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Dolles D, Nimczick M, Scheiner M, Ramler J, Stadtmüller P, Sawatzky E, Drakopoulos A, Sotriffer C, Wittmann H, Strasser A, Decker M. Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and h CB 2 R Ligands To Combat Neurodegenerative Disorders. ChemMedChem 2016;11:1270-83. [DOI: 10.1002/cmdc.201500418] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
21 Sachdev S, Cabalteja CC, Cheloha RW. Strategies for targeting cell surface proteins using multivalent conjugates and chemical biology. Methods Cell Biol 2021;166:205-22. [PMID: 34752333 DOI: 10.1016/bs.mcb.2021.06.004] [Reference Citation Analysis]
22 Cortés A, Casadó-Anguera V, Moreno E, Casadó V. The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndrome. Adv Pharmacol 2019;84:37-78. [PMID: 31229177 DOI: 10.1016/bs.apha.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Hryhorowicz S, Kaczmarek-Ryś M, Andrzejewska A, Staszak K, Hryhorowicz M, Korcz A, Słomski R. Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. Int J Mol Sci 2019;20:E5874. [PMID: 31771126 DOI: 10.3390/ijms20235874] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]